X-rays may show way to better Alzheimer's drugs
Researchers at Weizmann Institute have discovered the 3-D interaction between galanthamine and brain enzyme acetylcholinesterase (AChE), which breaks down neurotransmitter acetylcholine in Alzheimer's disease. This finding may lead to a new family of drugs with reduced side effects.